DDS- syndrome: a rare side effect of dapsone in leprosy patients
DOI:
https://doi.org/10.66344/jpad.15.2.2005.644Keywords:
Dapsone, DDS-, syndrome, jaundice, hepatotoxicityAbstract
A 35-year-old male suffering from mid-borderline leprosy was put on multidrug therapy. Sixweeks after the commencement of therapy he developed features of DDS- syndrome.Dapsone was immediately stopped, he was put on oral steroids. The patient graduallyimproved and the liver functions became normal within few weeks. The steroids weregradually tapered off. Dapsone was replaced with quinolones.References
Dutta RK. Erythema multiforme
bullosum due to dapsone. Lepr India
; 52: 306-9.
Browne SG. Antileprosy drugs. Br Med
J 1971; iv: 558-9.
Tomecki KJ, Catalano CJ. Dapsone
hypersensitivity: the sulphone syndrome
revisited. Arch Dermatol 1981; 117: 38-
Mohle-Boetani J, Akula SK, Holodniy
M. The sulphone syndrome in a patient
receiving dapsone prophylaxis for
Pneumocystis carinii pneumonia. West
J Med 1992; 156: 303-6.
Barnard GF, Scharf MJ, Dagher RK.
Sulphone syndrome in a patient
receiving steroids for pemphigus. Am J
Gastroenterol 1994: 89: 2057-9.
Saito S, lkezawa Z, Miyamoto H. A
case of dapsone syndrome. Clin Exp
Dermatol 1994; 19: 1520-6.
Chalasani P, Baffoe-Bonnie H, Jurado
RL. Dapsone therapy causing sulphone
syndrome and lethal hepatic failure in
an HIV infected patient. South Med J
; 87: 1450-6.
Bocquet H, Bourgault-Viliadal, Delfau-
Larue MH. Syndrome d,
hypersensitivity a la dapsone. Clone
Tcirculant transitoire. Ann Dermatol
Venereol 1995; 122: 514-6.
Prussick R, Shear NH. Dapsone
hypersensitivity syndrome. J Am Acad
Dermatol 1996; 35: 346-9.
Kumar R, Kumar M, Thappa D.
Dapsone syndrome-a five year
retrospective analysis. Ind J Lepr 1998;
: 271-6.
Reeve PA, Ala J, Hall JJ. Dapsone
syndrome in a Vanuatu: a high
incidence during multidrug treatment
(MDT) of leprosy. J Trop Med Hyg
; 95: 266-70.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
